Sir,
The paper by Carlin et al. 1 : I find of interest and worthy of comment. It provides a description of the guideline for diagnosing, both clinically and microbiologically, sexually acquired reactive arthritis (SARA) and for its subsequent management. It is reasonable, as the guideline indicates, that a search should be made for infection by Chlamydia trachomatis since it is the major cause of non-gonococcal urethritis (NGU) and the leading candidate as a cause of SARA. 2 In addition, if successful, the typing of any strain identified in the joint and/or genital tract at this time would help to assess, from a research aspect, the veracity or otherwise of the published notion, seemingly unlikely, that only ocular (trachoma: types A, B, Ba and C) and not genital chlamydial strains (types D to K) are involved in causing SARA. 2 Of course, such typing in uncomplicated NGU would be inappropriate because it would not affect the recommendations for patient management.
The second point is that among micro-organisms other than C. trachomatis that have been considered as NGU candidates, Mycoplasma genitalium is now regarded as an undoubted cause of this disease, so that a possible role in SARA is worthy of consideration. 2 Admittedly, this mycoplasma has been detected in the joint of only one patient with SARA, 3 possibly because it has not been widely sought at this site in the absence of appropriate nucleic acid amplification tests. In view of such molecular methods for detecting it now becoming more readily available, it would be remiss to spurn the opportunity of doing so, and even storing specimens for testing as a second best option. Success would, of course, raise the issue of the most appropriate treatment, particularly in the face of antibiotic resistance, discussed elsewhere. 4 Finally, it would seem that genitourinary and rheumatology clinicians working together would provide the best chance of expanding our knowledge of the role of this pathogenic mycoplasma in SARA and so inform future guidelines.
